SlideShare ist ein Scribd-Unternehmen logo
1 von 20
A Compliance Officer’s Guide to Surviving the Storm
Compliance Insight, Inc. 513-860-3512 Copyrighted 2013
What is an FDA Warning Letter
The United States Food and Drug Administration defines a Warning Letter as
"...a correspondence that notifies regulated industry about violations that
FDA has documented during its inspections or investigations. Typically, a
Warning Letter notifies a responsible individual or firm that the Agency
considers one or more products, practices, processes, or other activities to be
in violation of the Federal Food, Drug, and Cosmetic Act (the Act), its
implementing regulations and other federal statutes. Warning Letters should
only be issued for violations of regulatory significance, i.e., those that may
actually lead to an enforcement action if the documented violations are not
promptly and adequately corrected. A Warning Letter is one of the Agency’s
principal means of achieving prompt voluntary compliance with the Act.”
• Documents a violation of law or regulation
• Establishes that a firm or person has been
notified of the violation
• Your response to the FDA 483 may have been
deficient
• Designed to promote voluntary compliance
• Stepping stone to regulatory action
What does this letter mean for
you and your firm?
• Warning Letter is considered to be “prior
notice”
• Respond within 15 days
• FDA will initiate necessary action if no
response is received
• Time is CRITICAL – you have to organize,
understand, resolve and respond to the FDA
Before we begin on the response
work, let me say a few words about…
Two Approaches To Assessment
Focused
Assessment –
Based
specifically on
items from the
Warning Letter
Overall
Systemic
Assessment –
Look beyond
the specific
items, other
areas/products
Writing the Response
There are some basic rules that can be established
regarding writing a response letter. Some or all of
these rules may apply depending upon the particular
situation of the firm – e.g. lengthy list of
observations, serious issues on the warning letter,
etc.
Writing the Response
1. Someone in a high level in a Quality group (internal or external)
should write the response.
2. Personnel copied on the response should include high-level
management. This shows that management at the firm is aware
of the issues and the commitments being made.
3. Include a cover letter or opening statement. Tell the FDA that
you are serious about resolving the issues. State the site
address of the audit and the dates.
Writing the Response
4. Always remember that you are writing the response to the auditors
management – governmental auditing bodies do have supervisors and
managers. Do not assume that the person reading the report
understands the context of the observation or your reply.
5. Re-state the observation and reference number in the response.
Typically, the observation goes directly above the response.
6. If possible, indicate the related compliant systems. This shows that you
are in control and that some operations were functioning within
acceptable GMP parameters.
Writing the Response
7. If the action item is going to take some time to implement, state what
will be done in the interim to be compliant with GMPs. Don’t simply
indicate that actions will be taken in six months to correct the issue in
which you are currently out of compliance without addressing what you
will do to be compliant from the current date until the corrections are
implemented.
8. If corrective actions have already taken place, indicate the following:
• Dates implemented
• Training performed (copies of training sign-up sheets included)
• Copies of Purchase Orders, installation work, etc.
• Copies of updated SOPs – indicating what was changed.
Writing the Response
9. Define how enhancements will prevent recurrence of the issue
observed. Don’t assume that the reader will understand this fact.
10. Explain what will be done to expand, enhance or streamline the
compliance system.
11. Don’t forget about training. Allow sufficient time to implement
changes to incorporate training that may include proficiency
testing.
Writing the Response
12. Describe how the firm will monitor the progress and effectiveness of the
corrective actions.
13. It may be helpful to explain that despite the issues noted, there has never been
an issue. It is not advisable to use this response tactic each time but it can be
advantageous for critical observations to state something on the order of “…the
product has always met predetermined quality parameters…”
14. Revise, revise, revise. Allow other people not directly involved with the audit to
review and comment on the response. They may have insight on response
wording that would assist in clarification or strengthening of points.
How the response should look
Indicating corrective actions – taken or
planned
Restating the observation or
comments
Defining root cause
Developing the due date
When initially formulating a response, a 4-Stage Inspection Response
Approach may be helpful to develop perceptive on the format of the
response and contribute to a better understanding of what actually needs to
be implemented to be compliant. This type of approach includes
Item
1
Item
2
Item
3
Item
4
Cover Letter Example – this is
from top level management…
We are in receipt of your communication dated --- on -----. We take your
communication very seriously and commit ourselves to address your
concerns adequately and expeditiously. We will take all the necessary
measures to ensure our customers' well-being and safety. Enclosed please
find an attachment that addresses your concerns on an individual and on a
systematic basis.
We agree that a sound Quality System is the result of effective
management commitment, dedicated employees, and sound processes
and practices.
To that end we have retained _____, a reputable consulting firm, to assess
our Quality System in greater detail and to help ensure that our Corrective
Action plan will address all systemic issues effectively. We have attached a
qualification profile for your review.
Response Letter – from the
response team
xx June 20xx
U.S. Food and Drug Administration
c/o <name>, Compliance Officer
<address>
<city>, <state> <zip>
Re: Warning Letter xxx
Dear Mr. xxx:
This letter provides the response from <company name> to the Food and Drug Administration’s (FDA) Warning Letter dated xxx
(Attachment 1) related to findings from FDA’s inspection of xxx facility on xxx through xxx. As the Warning Letter notes, xxx
responded to the FDA Form 483 on xxx (Attachment 2 for the 483 and original response) but notes that it “did not provide any
detailed information regarding proposed corrective actions.” To address this point, xxx is also including a more in-depth response, as
part of this letter to the original 483 observations.
xxx takes seriously its responsibilities in providing a quality product to the public. It continues to be xxx objective to operate in
accordance with current regulations as stipulated by the US FDA. We value your communication and commit to meeting current
GMP requirements. To this end, xxx has executed xxx critically important actions:
W.L. Observation
During the inspection, our investigators observed and documented xxx conditions. An analysis of your xxx
collected during the inspection found significant xxx contamination.
Response
In conjunction with the conditions noted, xxx has initiated the following:
xxx
Implementation and maintenance of a clean and compliant environment has been executed as detailed
previously but includes the following highlights:
xxx
Pursuant to the situation as outlined by the FDA testing of the xxx, xxx initiated a recall of the lot in xxx.
The investigation into the situation that caused this incident indicated the following highlights:
xxx
Root Cause of the Situation:
xxx
Action Plan
As applicable…
Due Date
Beyond the Context of the Direct
Observations
• A systemic response to any audit observations must equate to a
systemic resolution to any issues within the firm.
• This action requires further evaluation than just actions in a
system at a company site.
• The FDA in particular will require that all company sites implement
corrective actions along the same plan of action.
• Failure to do so may result in further regulatory actions.
• Programs need to be established which require any observations
and the responses to be circulated for evaluation within a
company to determine if other areas are non-compliant.
Be Sure to Visit Us On-Line or Call…
Our website is filled with lots of tips
and guidance on FDA 483’s, Warning
Letters and more. Visit us at:
www.Compliance-Insight.com
You can easily contact us for more
help in dealing with FDA Warning
Letters by calling us at 513-860-3512
www.Compliance-Insight.com
Call us at 513-860-3512
Email us at
FDAWarningLetterTeam@Compliance-Insight.com
Questions? Comments?
We are happy to help you!

Weitere ähnliche Inhalte

Was ist angesagt?

GOOD LABORATORY PRACTICES(GLP).pptx
GOOD LABORATORY PRACTICES(GLP).pptxGOOD LABORATORY PRACTICES(GLP).pptx
GOOD LABORATORY PRACTICES(GLP).pptxreechashah2
 
Good Automated Laboratory Practices
Good Automated Laboratory PracticesGood Automated Laboratory Practices
Good Automated Laboratory PracticesSwapnil Fernandes
 
GOOD AUTOMATED LABORATORY PRACTICE
GOOD AUTOMATED LABORATORY PRACTICEGOOD AUTOMATED LABORATORY PRACTICE
GOOD AUTOMATED LABORATORY PRACTICEjagrutivasava
 
FDA Inspections ( How to Survive an FDA Inspection).ppt
FDA Inspections ( How to Survive an FDA Inspection).pptFDA Inspections ( How to Survive an FDA Inspection).ppt
FDA Inspections ( How to Survive an FDA Inspection).pptshaik malangsha
 
Site master file
Site master fileSite master file
Site master fileSridhar S
 
FDA PreApproval Inspection - Part 2
FDA PreApproval Inspection - Part 2FDA PreApproval Inspection - Part 2
FDA PreApproval Inspection - Part 2Jorge Torres
 
Case study on change control in equipment
Case study on change control in equipmentCase study on change control in equipment
Case study on change control in equipmentS S N D Balakrishna Ch
 
Batch Review And Batch Release.pptx
Batch Review And Batch Release.pptxBatch Review And Batch Release.pptx
Batch Review And Batch Release.pptxAbhishekJadhav189260
 
Product Registration Guidlines
Product Registration GuidlinesProduct Registration Guidlines
Product Registration GuidlinesSagar Bagul
 
GMP compliances of Audit
GMP compliances of AuditGMP compliances of Audit
GMP compliances of AuditMegha bhise
 
AUDIT - AUDITING STRATEGIES.pptx
AUDIT - AUDITING STRATEGIES.pptxAUDIT - AUDITING STRATEGIES.pptx
AUDIT - AUDITING STRATEGIES.pptxMohamed Fazil M
 
Center for Biologics Evaluation and Research
Center for Biologics Evaluation and ResearchCenter for Biologics Evaluation and Research
Center for Biologics Evaluation and ResearchRajeswariS12
 
FDA PreApproval Inspection - Part 1
FDA PreApproval Inspection - Part 1FDA PreApproval Inspection - Part 1
FDA PreApproval Inspection - Part 1Jorge Torres
 
21CFR 320- BIO AVAILABILITY AND BIO EQUIVALENCE REQUIREMENTS
21CFR 320- BIO AVAILABILITY AND BIO EQUIVALENCE REQUIREMENTS21CFR 320- BIO AVAILABILITY AND BIO EQUIVALENCE REQUIREMENTS
21CFR 320- BIO AVAILABILITY AND BIO EQUIVALENCE REQUIREMENTSPallavi Christeen
 
chemical_based_hazard, M.Pharm ,Sem 2, Bhumi Suratiya.pptx
chemical_based_hazard, M.Pharm ,Sem 2, Bhumi Suratiya.pptxchemical_based_hazard, M.Pharm ,Sem 2, Bhumi Suratiya.pptx
chemical_based_hazard, M.Pharm ,Sem 2, Bhumi Suratiya.pptxBhumiSuratiya
 
NEW ERA OF DRUG PRODUCT: OPPORTUNITIES AND CHALLENGES
NEW ERA OF DRUG PRODUCT: OPPORTUNITIES AND CHALLENGESNEW ERA OF DRUG PRODUCT: OPPORTUNITIES AND CHALLENGES
NEW ERA OF DRUG PRODUCT: OPPORTUNITIES AND CHALLENGESganpat420
 

Was ist angesagt? (20)

GOOD LABORATORY PRACTICES(GLP).pptx
GOOD LABORATORY PRACTICES(GLP).pptxGOOD LABORATORY PRACTICES(GLP).pptx
GOOD LABORATORY PRACTICES(GLP).pptx
 
Good Automated Laboratory Practices
Good Automated Laboratory PracticesGood Automated Laboratory Practices
Good Automated Laboratory Practices
 
GOOD AUTOMATED LABORATORY PRACTICE
GOOD AUTOMATED LABORATORY PRACTICEGOOD AUTOMATED LABORATORY PRACTICE
GOOD AUTOMATED LABORATORY PRACTICE
 
FDA Inspections ( How to Survive an FDA Inspection).ppt
FDA Inspections ( How to Survive an FDA Inspection).pptFDA Inspections ( How to Survive an FDA Inspection).ppt
FDA Inspections ( How to Survive an FDA Inspection).ppt
 
Ghtf study group 4
Ghtf study group 4Ghtf study group 4
Ghtf study group 4
 
Site master file
Site master fileSite master file
Site master file
 
FDA 483
FDA 483FDA 483
FDA 483
 
FDA PreApproval Inspection - Part 2
FDA PreApproval Inspection - Part 2FDA PreApproval Inspection - Part 2
FDA PreApproval Inspection - Part 2
 
Case study on change control in equipment
Case study on change control in equipmentCase study on change control in equipment
Case study on change control in equipment
 
Batch Review And Batch Release.pptx
Batch Review And Batch Release.pptxBatch Review And Batch Release.pptx
Batch Review And Batch Release.pptx
 
ICH Q7 Guideline
ICH Q7 GuidelineICH Q7 Guideline
ICH Q7 Guideline
 
Product Registration Guidlines
Product Registration GuidlinesProduct Registration Guidlines
Product Registration Guidlines
 
GMP compliances of Audit
GMP compliances of AuditGMP compliances of Audit
GMP compliances of Audit
 
AUDIT - AUDITING STRATEGIES.pptx
AUDIT - AUDITING STRATEGIES.pptxAUDIT - AUDITING STRATEGIES.pptx
AUDIT - AUDITING STRATEGIES.pptx
 
Center for Biologics Evaluation and Research
Center for Biologics Evaluation and ResearchCenter for Biologics Evaluation and Research
Center for Biologics Evaluation and Research
 
FDA PreApproval Inspection - Part 1
FDA PreApproval Inspection - Part 1FDA PreApproval Inspection - Part 1
FDA PreApproval Inspection - Part 1
 
21CFR 320- BIO AVAILABILITY AND BIO EQUIVALENCE REQUIREMENTS
21CFR 320- BIO AVAILABILITY AND BIO EQUIVALENCE REQUIREMENTS21CFR 320- BIO AVAILABILITY AND BIO EQUIVALENCE REQUIREMENTS
21CFR 320- BIO AVAILABILITY AND BIO EQUIVALENCE REQUIREMENTS
 
chemical_based_hazard, M.Pharm ,Sem 2, Bhumi Suratiya.pptx
chemical_based_hazard, M.Pharm ,Sem 2, Bhumi Suratiya.pptxchemical_based_hazard, M.Pharm ,Sem 2, Bhumi Suratiya.pptx
chemical_based_hazard, M.Pharm ,Sem 2, Bhumi Suratiya.pptx
 
NEW ERA OF DRUG PRODUCT: OPPORTUNITIES AND CHALLENGES
NEW ERA OF DRUG PRODUCT: OPPORTUNITIES AND CHALLENGESNEW ERA OF DRUG PRODUCT: OPPORTUNITIES AND CHALLENGES
NEW ERA OF DRUG PRODUCT: OPPORTUNITIES AND CHALLENGES
 
ICH Q7 Guideline
ICH Q7 GuidelineICH Q7 Guideline
ICH Q7 Guideline
 

Ähnlich wie FDA Warning Letter

FDA Inspections: Handling the Consequences. Dealing with the aftermath of an...
FDA Inspections: Handling the Consequences.  Dealing with the aftermath of an...FDA Inspections: Handling the Consequences.  Dealing with the aftermath of an...
FDA Inspections: Handling the Consequences. Dealing with the aftermath of an...Michael Swit
 
FDA Warning Letters: Key Legal and Tactical Issues in Dealing with FDA's "Sh...
FDA Warning Letters:  Key Legal and Tactical Issues in Dealing with FDA's "Sh...FDA Warning Letters:  Key Legal and Tactical Issues in Dealing with FDA's "Sh...
FDA Warning Letters: Key Legal and Tactical Issues in Dealing with FDA's "Sh...Michael Swit
 
FDA Enforcement -- the Perils of Inadequate Compliance
FDA Enforcement -- the Perils of Inadequate ComplianceFDA Enforcement -- the Perils of Inadequate Compliance
FDA Enforcement -- the Perils of Inadequate ComplianceMichael Swit
 
FDA Enforcement -- the Perils of Inadequate Compliance
FDA Enforcement -- the Perils of Inadequate ComplianceFDA Enforcement -- the Perils of Inadequate Compliance
FDA Enforcement -- the Perils of Inadequate ComplianceMichael Swit
 
FDA’s New Strategy on Enforcement: The Growing Perils of Inadequate Compliance
FDA’s New Strategy on Enforcement: The Growing Perils of Inadequate ComplianceFDA’s New Strategy on Enforcement: The Growing Perils of Inadequate Compliance
FDA’s New Strategy on Enforcement: The Growing Perils of Inadequate ComplianceMichael Swit
 
Leveraging Corporate Integrity Agreements for Healthcare Compliance
Leveraging Corporate Integrity Agreements for Healthcare ComplianceLeveraging Corporate Integrity Agreements for Healthcare Compliance
Leveraging Corporate Integrity Agreements for Healthcare CompliancePolsinelli PC
 
Dashboard Benchmark Evaluation.docx
Dashboard Benchmark Evaluation.docxDashboard Benchmark Evaluation.docx
Dashboard Benchmark Evaluation.docxwrite31
 
3 ISO 14001-2015 EMS Awareness Training Material (Module 2).pdf
3 ISO 14001-2015 EMS Awareness Training Material (Module 2).pdf3 ISO 14001-2015 EMS Awareness Training Material (Module 2).pdf
3 ISO 14001-2015 EMS Awareness Training Material (Module 2).pdfManivannanVelayuthan
 
Auditing Basics
Auditing BasicsAuditing Basics
Auditing BasicsMaan M
 
Course ReportFor the Unit VII Assignment, you are asked to d.docx
 Course  ReportFor the Unit VII Assignment, you are asked to d.docx Course  ReportFor the Unit VII Assignment, you are asked to d.docx
Course ReportFor the Unit VII Assignment, you are asked to d.docxaryan532920
 
Audit vs inspection
Audit vs inspectionAudit vs inspection
Audit vs inspectionmazrulazman
 
The Role of Regulatory GMP Audit in Pharmaceutical Companies.
The Role of Regulatory GMP Audit in Pharmaceutical Companies.The Role of Regulatory GMP Audit in Pharmaceutical Companies.
The Role of Regulatory GMP Audit in Pharmaceutical Companies.Jitendra Sonawane
 
Focus on FDA cGMPs inspections
Focus on FDA cGMPs inspections Focus on FDA cGMPs inspections
Focus on FDA cGMPs inspections JinalPrajapati13
 
Form483 warning letter issued to pharmaceutical companies by Bindu Kshtriya
Form483 warning letter issued to pharmaceutical companies by Bindu KshtriyaForm483 warning letter issued to pharmaceutical companies by Bindu Kshtriya
Form483 warning letter issued to pharmaceutical companies by Bindu KshtriyaBindu Kshtriya
 
FDA warning letter-Quick Review-India
FDA warning letter-Quick Review-IndiaFDA warning letter-Quick Review-India
FDA warning letter-Quick Review-IndiaTech Observer
 

Ähnlich wie FDA Warning Letter (20)

FDA Inspections: Handling the Consequences. Dealing with the aftermath of an...
FDA Inspections: Handling the Consequences.  Dealing with the aftermath of an...FDA Inspections: Handling the Consequences.  Dealing with the aftermath of an...
FDA Inspections: Handling the Consequences. Dealing with the aftermath of an...
 
FDA Warning Letters: Key Legal and Tactical Issues in Dealing with FDA's "Sh...
FDA Warning Letters:  Key Legal and Tactical Issues in Dealing with FDA's "Sh...FDA Warning Letters:  Key Legal and Tactical Issues in Dealing with FDA's "Sh...
FDA Warning Letters: Key Legal and Tactical Issues in Dealing with FDA's "Sh...
 
Quality audit plan
Quality audit planQuality audit plan
Quality audit plan
 
FDA Enforcement -- the Perils of Inadequate Compliance
FDA Enforcement -- the Perils of Inadequate ComplianceFDA Enforcement -- the Perils of Inadequate Compliance
FDA Enforcement -- the Perils of Inadequate Compliance
 
FDA Enforcement -- the Perils of Inadequate Compliance
FDA Enforcement -- the Perils of Inadequate ComplianceFDA Enforcement -- the Perils of Inadequate Compliance
FDA Enforcement -- the Perils of Inadequate Compliance
 
FDA’s New Strategy on Enforcement: The Growing Perils of Inadequate Compliance
FDA’s New Strategy on Enforcement: The Growing Perils of Inadequate ComplianceFDA’s New Strategy on Enforcement: The Growing Perils of Inadequate Compliance
FDA’s New Strategy on Enforcement: The Growing Perils of Inadequate Compliance
 
Leveraging Corporate Integrity Agreements for Healthcare Compliance
Leveraging Corporate Integrity Agreements for Healthcare ComplianceLeveraging Corporate Integrity Agreements for Healthcare Compliance
Leveraging Corporate Integrity Agreements for Healthcare Compliance
 
Dashboard Benchmark Evaluation.docx
Dashboard Benchmark Evaluation.docxDashboard Benchmark Evaluation.docx
Dashboard Benchmark Evaluation.docx
 
3 ISO 14001-2015 EMS Awareness Training Material (Module 2).pdf
3 ISO 14001-2015 EMS Awareness Training Material (Module 2).pdf3 ISO 14001-2015 EMS Awareness Training Material (Module 2).pdf
3 ISO 14001-2015 EMS Awareness Training Material (Module 2).pdf
 
DEVA_WP_mc_final_2.0
DEVA_WP_mc_final_2.0DEVA_WP_mc_final_2.0
DEVA_WP_mc_final_2.0
 
Auditing Basics
Auditing BasicsAuditing Basics
Auditing Basics
 
Pai
PaiPai
Pai
 
Course ReportFor the Unit VII Assignment, you are asked to d.docx
 Course  ReportFor the Unit VII Assignment, you are asked to d.docx Course  ReportFor the Unit VII Assignment, you are asked to d.docx
Course ReportFor the Unit VII Assignment, you are asked to d.docx
 
Qsm guidelines
Qsm guidelinesQsm guidelines
Qsm guidelines
 
Audit vs inspection
Audit vs inspectionAudit vs inspection
Audit vs inspection
 
The Role of Regulatory GMP Audit in Pharmaceutical Companies.
The Role of Regulatory GMP Audit in Pharmaceutical Companies.The Role of Regulatory GMP Audit in Pharmaceutical Companies.
The Role of Regulatory GMP Audit in Pharmaceutical Companies.
 
Focus on FDA cGMPs inspections
Focus on FDA cGMPs inspections Focus on FDA cGMPs inspections
Focus on FDA cGMPs inspections
 
Data Protection & GDPR Health Check Service Overview
Data Protection & GDPR Health Check Service OverviewData Protection & GDPR Health Check Service Overview
Data Protection & GDPR Health Check Service Overview
 
Form483 warning letter issued to pharmaceutical companies by Bindu Kshtriya
Form483 warning letter issued to pharmaceutical companies by Bindu KshtriyaForm483 warning letter issued to pharmaceutical companies by Bindu Kshtriya
Form483 warning letter issued to pharmaceutical companies by Bindu Kshtriya
 
FDA warning letter-Quick Review-India
FDA warning letter-Quick Review-IndiaFDA warning letter-Quick Review-India
FDA warning letter-Quick Review-India
 

Mehr von Compliance Insight, Inc. (15)

July 2015
July 2015July 2015
July 2015
 
GCP Overview by Compliance Insight, Inc.
GCP Overview by Compliance Insight, Inc.GCP Overview by Compliance Insight, Inc.
GCP Overview by Compliance Insight, Inc.
 
FDA audit series part 5, dealing with the 483 or Warning Letter
FDA audit series   part 5, dealing with the 483 or Warning LetterFDA audit series   part 5, dealing with the 483 or Warning Letter
FDA audit series part 5, dealing with the 483 or Warning Letter
 
FDA audit series part 4, the closeout
FDA audit series   part 4, the closeoutFDA audit series   part 4, the closeout
FDA audit series part 4, the closeout
 
Fda audit series part 3, while the fda is there
Fda audit series   part 3, while the fda is  thereFda audit series   part 3, while the fda is  there
Fda audit series part 3, while the fda is there
 
FDA audit series part 2, what to do when the FDA arrives
FDA audit series   part 2, what to do when the FDA arrivesFDA audit series   part 2, what to do when the FDA arrives
FDA audit series part 2, what to do when the FDA arrives
 
FDA audit series part 1, Preparing for the Audit
FDA audit series   part 1, Preparing for the AuditFDA audit series   part 1, Preparing for the Audit
FDA audit series part 1, Preparing for the Audit
 
About Compliance Insight Inc.
About Compliance Insight Inc.About Compliance Insight Inc.
About Compliance Insight Inc.
 
FDA 483 observations in the lab
FDA 483 observations in the labFDA 483 observations in the lab
FDA 483 observations in the lab
 
Basics of FDA GMP Training
Basics of FDA GMP TrainingBasics of FDA GMP Training
Basics of FDA GMP Training
 
FDA Audit - The Do and Don't List
FDA Audit - The Do and Don't ListFDA Audit - The Do and Don't List
FDA Audit - The Do and Don't List
 
FDA GMP Training - The Quality Audit
FDA GMP Training - The Quality AuditFDA GMP Training - The Quality Audit
FDA GMP Training - The Quality Audit
 
Top 22 Tips: Writing For FDA Compliance
Top 22 Tips: Writing For FDA ComplianceTop 22 Tips: Writing For FDA Compliance
Top 22 Tips: Writing For FDA Compliance
 
21 cfr, parts 210 211
21 cfr, parts 210 21121 cfr, parts 210 211
21 cfr, parts 210 211
 
Fda Inspection
Fda InspectionFda Inspection
Fda Inspection
 

Kürzlich hochgeladen

Call Girls Pune Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Pune Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Pune Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Pune Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
0183760ssssssssssssssssssssssssssss00101011 (27).pdf
0183760ssssssssssssssssssssssssssss00101011 (27).pdf0183760ssssssssssssssssssssssssssss00101011 (27).pdf
0183760ssssssssssssssssssssssssssss00101011 (27).pdfRenandantas16
 
Cash Payment 9602870969 Escort Service in Udaipur Call Girls
Cash Payment 9602870969 Escort Service in Udaipur Call GirlsCash Payment 9602870969 Escort Service in Udaipur Call Girls
Cash Payment 9602870969 Escort Service in Udaipur Call GirlsApsara Of India
 
Progress Report - Oracle Database Analyst Summit
Progress  Report - Oracle Database Analyst SummitProgress  Report - Oracle Database Analyst Summit
Progress Report - Oracle Database Analyst SummitHolger Mueller
 
It will be International Nurses' Day on 12 May
It will be International Nurses' Day on 12 MayIt will be International Nurses' Day on 12 May
It will be International Nurses' Day on 12 MayNZSG
 
Monthly Social Media Update April 2024 pptx.pptx
Monthly Social Media Update April 2024 pptx.pptxMonthly Social Media Update April 2024 pptx.pptx
Monthly Social Media Update April 2024 pptx.pptxAndy Lambert
 
Call Girls In Panjim North Goa 9971646499 Genuine Service
Call Girls In Panjim North Goa 9971646499 Genuine ServiceCall Girls In Panjim North Goa 9971646499 Genuine Service
Call Girls In Panjim North Goa 9971646499 Genuine Serviceritikaroy0888
 
Value Proposition canvas- Customer needs and pains
Value Proposition canvas- Customer needs and painsValue Proposition canvas- Customer needs and pains
Value Proposition canvas- Customer needs and painsP&CO
 
BEST ✨ Call Girls In Indirapuram Ghaziabad ✔️ 9871031762 ✔️ Escorts Service...
BEST ✨ Call Girls In  Indirapuram Ghaziabad  ✔️ 9871031762 ✔️ Escorts Service...BEST ✨ Call Girls In  Indirapuram Ghaziabad  ✔️ 9871031762 ✔️ Escorts Service...
BEST ✨ Call Girls In Indirapuram Ghaziabad ✔️ 9871031762 ✔️ Escorts Service...noida100girls
 
Best Basmati Rice Manufacturers in India
Best Basmati Rice Manufacturers in IndiaBest Basmati Rice Manufacturers in India
Best Basmati Rice Manufacturers in IndiaShree Krishna Exports
 
Call Girls Navi Mumbai Just Call 9907093804 Top Class Call Girl Service Avail...
Call Girls Navi Mumbai Just Call 9907093804 Top Class Call Girl Service Avail...Call Girls Navi Mumbai Just Call 9907093804 Top Class Call Girl Service Avail...
Call Girls Navi Mumbai Just Call 9907093804 Top Class Call Girl Service Avail...Dipal Arora
 
VIP Kolkata Call Girl Howrah 👉 8250192130 Available With Room
VIP Kolkata Call Girl Howrah 👉 8250192130  Available With RoomVIP Kolkata Call Girl Howrah 👉 8250192130  Available With Room
VIP Kolkata Call Girl Howrah 👉 8250192130 Available With Roomdivyansh0kumar0
 
Insurers' journeys to build a mastery in the IoT usage
Insurers' journeys to build a mastery in the IoT usageInsurers' journeys to build a mastery in the IoT usage
Insurers' journeys to build a mastery in the IoT usageMatteo Carbone
 
Best VIP Call Girls Noida Sector 40 Call Me: 8448380779
Best VIP Call Girls Noida Sector 40 Call Me: 8448380779Best VIP Call Girls Noida Sector 40 Call Me: 8448380779
Best VIP Call Girls Noida Sector 40 Call Me: 8448380779Delhi Call girls
 
Tech Startup Growth Hacking 101 - Basics on Growth Marketing
Tech Startup Growth Hacking 101  - Basics on Growth MarketingTech Startup Growth Hacking 101  - Basics on Growth Marketing
Tech Startup Growth Hacking 101 - Basics on Growth MarketingShawn Pang
 
Mysore Call Girls 8617370543 WhatsApp Number 24x7 Best Services
Mysore Call Girls 8617370543 WhatsApp Number 24x7 Best ServicesMysore Call Girls 8617370543 WhatsApp Number 24x7 Best Services
Mysore Call Girls 8617370543 WhatsApp Number 24x7 Best ServicesDipal Arora
 
M.C Lodges -- Guest House in Jhang.
M.C Lodges --  Guest House in Jhang.M.C Lodges --  Guest House in Jhang.
M.C Lodges -- Guest House in Jhang.Aaiza Hassan
 
Lucknow 💋 Escorts in Lucknow - 450+ Call Girl Cash Payment 8923113531 Neha Th...
Lucknow 💋 Escorts in Lucknow - 450+ Call Girl Cash Payment 8923113531 Neha Th...Lucknow 💋 Escorts in Lucknow - 450+ Call Girl Cash Payment 8923113531 Neha Th...
Lucknow 💋 Escorts in Lucknow - 450+ Call Girl Cash Payment 8923113531 Neha Th...anilsa9823
 
Ensure the security of your HCL environment by applying the Zero Trust princi...
Ensure the security of your HCL environment by applying the Zero Trust princi...Ensure the security of your HCL environment by applying the Zero Trust princi...
Ensure the security of your HCL environment by applying the Zero Trust princi...Roland Driesen
 

Kürzlich hochgeladen (20)

Call Girls Pune Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Pune Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Pune Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Pune Just Call 9907093804 Top Class Call Girl Service Available
 
0183760ssssssssssssssssssssssssssss00101011 (27).pdf
0183760ssssssssssssssssssssssssssss00101011 (27).pdf0183760ssssssssssssssssssssssssssss00101011 (27).pdf
0183760ssssssssssssssssssssssssssss00101011 (27).pdf
 
Cash Payment 9602870969 Escort Service in Udaipur Call Girls
Cash Payment 9602870969 Escort Service in Udaipur Call GirlsCash Payment 9602870969 Escort Service in Udaipur Call Girls
Cash Payment 9602870969 Escort Service in Udaipur Call Girls
 
Progress Report - Oracle Database Analyst Summit
Progress  Report - Oracle Database Analyst SummitProgress  Report - Oracle Database Analyst Summit
Progress Report - Oracle Database Analyst Summit
 
It will be International Nurses' Day on 12 May
It will be International Nurses' Day on 12 MayIt will be International Nurses' Day on 12 May
It will be International Nurses' Day on 12 May
 
Monthly Social Media Update April 2024 pptx.pptx
Monthly Social Media Update April 2024 pptx.pptxMonthly Social Media Update April 2024 pptx.pptx
Monthly Social Media Update April 2024 pptx.pptx
 
Call Girls In Panjim North Goa 9971646499 Genuine Service
Call Girls In Panjim North Goa 9971646499 Genuine ServiceCall Girls In Panjim North Goa 9971646499 Genuine Service
Call Girls In Panjim North Goa 9971646499 Genuine Service
 
Value Proposition canvas- Customer needs and pains
Value Proposition canvas- Customer needs and painsValue Proposition canvas- Customer needs and pains
Value Proposition canvas- Customer needs and pains
 
BEST ✨ Call Girls In Indirapuram Ghaziabad ✔️ 9871031762 ✔️ Escorts Service...
BEST ✨ Call Girls In  Indirapuram Ghaziabad  ✔️ 9871031762 ✔️ Escorts Service...BEST ✨ Call Girls In  Indirapuram Ghaziabad  ✔️ 9871031762 ✔️ Escorts Service...
BEST ✨ Call Girls In Indirapuram Ghaziabad ✔️ 9871031762 ✔️ Escorts Service...
 
Best Basmati Rice Manufacturers in India
Best Basmati Rice Manufacturers in IndiaBest Basmati Rice Manufacturers in India
Best Basmati Rice Manufacturers in India
 
Call Girls Navi Mumbai Just Call 9907093804 Top Class Call Girl Service Avail...
Call Girls Navi Mumbai Just Call 9907093804 Top Class Call Girl Service Avail...Call Girls Navi Mumbai Just Call 9907093804 Top Class Call Girl Service Avail...
Call Girls Navi Mumbai Just Call 9907093804 Top Class Call Girl Service Avail...
 
Forklift Operations: Safety through Cartoons
Forklift Operations: Safety through CartoonsForklift Operations: Safety through Cartoons
Forklift Operations: Safety through Cartoons
 
VIP Kolkata Call Girl Howrah 👉 8250192130 Available With Room
VIP Kolkata Call Girl Howrah 👉 8250192130  Available With RoomVIP Kolkata Call Girl Howrah 👉 8250192130  Available With Room
VIP Kolkata Call Girl Howrah 👉 8250192130 Available With Room
 
Insurers' journeys to build a mastery in the IoT usage
Insurers' journeys to build a mastery in the IoT usageInsurers' journeys to build a mastery in the IoT usage
Insurers' journeys to build a mastery in the IoT usage
 
Best VIP Call Girls Noida Sector 40 Call Me: 8448380779
Best VIP Call Girls Noida Sector 40 Call Me: 8448380779Best VIP Call Girls Noida Sector 40 Call Me: 8448380779
Best VIP Call Girls Noida Sector 40 Call Me: 8448380779
 
Tech Startup Growth Hacking 101 - Basics on Growth Marketing
Tech Startup Growth Hacking 101  - Basics on Growth MarketingTech Startup Growth Hacking 101  - Basics on Growth Marketing
Tech Startup Growth Hacking 101 - Basics on Growth Marketing
 
Mysore Call Girls 8617370543 WhatsApp Number 24x7 Best Services
Mysore Call Girls 8617370543 WhatsApp Number 24x7 Best ServicesMysore Call Girls 8617370543 WhatsApp Number 24x7 Best Services
Mysore Call Girls 8617370543 WhatsApp Number 24x7 Best Services
 
M.C Lodges -- Guest House in Jhang.
M.C Lodges --  Guest House in Jhang.M.C Lodges --  Guest House in Jhang.
M.C Lodges -- Guest House in Jhang.
 
Lucknow 💋 Escorts in Lucknow - 450+ Call Girl Cash Payment 8923113531 Neha Th...
Lucknow 💋 Escorts in Lucknow - 450+ Call Girl Cash Payment 8923113531 Neha Th...Lucknow 💋 Escorts in Lucknow - 450+ Call Girl Cash Payment 8923113531 Neha Th...
Lucknow 💋 Escorts in Lucknow - 450+ Call Girl Cash Payment 8923113531 Neha Th...
 
Ensure the security of your HCL environment by applying the Zero Trust princi...
Ensure the security of your HCL environment by applying the Zero Trust princi...Ensure the security of your HCL environment by applying the Zero Trust princi...
Ensure the security of your HCL environment by applying the Zero Trust princi...
 

FDA Warning Letter

  • 1. A Compliance Officer’s Guide to Surviving the Storm Compliance Insight, Inc. 513-860-3512 Copyrighted 2013
  • 2. What is an FDA Warning Letter The United States Food and Drug Administration defines a Warning Letter as "...a correspondence that notifies regulated industry about violations that FDA has documented during its inspections or investigations. Typically, a Warning Letter notifies a responsible individual or firm that the Agency considers one or more products, practices, processes, or other activities to be in violation of the Federal Food, Drug, and Cosmetic Act (the Act), its implementing regulations and other federal statutes. Warning Letters should only be issued for violations of regulatory significance, i.e., those that may actually lead to an enforcement action if the documented violations are not promptly and adequately corrected. A Warning Letter is one of the Agency’s principal means of achieving prompt voluntary compliance with the Act.”
  • 3. • Documents a violation of law or regulation • Establishes that a firm or person has been notified of the violation • Your response to the FDA 483 may have been deficient • Designed to promote voluntary compliance • Stepping stone to regulatory action
  • 4. What does this letter mean for you and your firm? • Warning Letter is considered to be “prior notice” • Respond within 15 days • FDA will initiate necessary action if no response is received • Time is CRITICAL – you have to organize, understand, resolve and respond to the FDA
  • 5. Before we begin on the response work, let me say a few words about…
  • 6. Two Approaches To Assessment Focused Assessment – Based specifically on items from the Warning Letter Overall Systemic Assessment – Look beyond the specific items, other areas/products
  • 7. Writing the Response There are some basic rules that can be established regarding writing a response letter. Some or all of these rules may apply depending upon the particular situation of the firm – e.g. lengthy list of observations, serious issues on the warning letter, etc.
  • 8. Writing the Response 1. Someone in a high level in a Quality group (internal or external) should write the response. 2. Personnel copied on the response should include high-level management. This shows that management at the firm is aware of the issues and the commitments being made. 3. Include a cover letter or opening statement. Tell the FDA that you are serious about resolving the issues. State the site address of the audit and the dates.
  • 9. Writing the Response 4. Always remember that you are writing the response to the auditors management – governmental auditing bodies do have supervisors and managers. Do not assume that the person reading the report understands the context of the observation or your reply. 5. Re-state the observation and reference number in the response. Typically, the observation goes directly above the response. 6. If possible, indicate the related compliant systems. This shows that you are in control and that some operations were functioning within acceptable GMP parameters.
  • 10. Writing the Response 7. If the action item is going to take some time to implement, state what will be done in the interim to be compliant with GMPs. Don’t simply indicate that actions will be taken in six months to correct the issue in which you are currently out of compliance without addressing what you will do to be compliant from the current date until the corrections are implemented. 8. If corrective actions have already taken place, indicate the following: • Dates implemented • Training performed (copies of training sign-up sheets included) • Copies of Purchase Orders, installation work, etc. • Copies of updated SOPs – indicating what was changed.
  • 11. Writing the Response 9. Define how enhancements will prevent recurrence of the issue observed. Don’t assume that the reader will understand this fact. 10. Explain what will be done to expand, enhance or streamline the compliance system. 11. Don’t forget about training. Allow sufficient time to implement changes to incorporate training that may include proficiency testing.
  • 12. Writing the Response 12. Describe how the firm will monitor the progress and effectiveness of the corrective actions. 13. It may be helpful to explain that despite the issues noted, there has never been an issue. It is not advisable to use this response tactic each time but it can be advantageous for critical observations to state something on the order of “…the product has always met predetermined quality parameters…” 14. Revise, revise, revise. Allow other people not directly involved with the audit to review and comment on the response. They may have insight on response wording that would assist in clarification or strengthening of points.
  • 13. How the response should look
  • 14. Indicating corrective actions – taken or planned Restating the observation or comments Defining root cause Developing the due date When initially formulating a response, a 4-Stage Inspection Response Approach may be helpful to develop perceptive on the format of the response and contribute to a better understanding of what actually needs to be implemented to be compliant. This type of approach includes Item 1 Item 2 Item 3 Item 4
  • 15. Cover Letter Example – this is from top level management… We are in receipt of your communication dated --- on -----. We take your communication very seriously and commit ourselves to address your concerns adequately and expeditiously. We will take all the necessary measures to ensure our customers' well-being and safety. Enclosed please find an attachment that addresses your concerns on an individual and on a systematic basis. We agree that a sound Quality System is the result of effective management commitment, dedicated employees, and sound processes and practices. To that end we have retained _____, a reputable consulting firm, to assess our Quality System in greater detail and to help ensure that our Corrective Action plan will address all systemic issues effectively. We have attached a qualification profile for your review.
  • 16. Response Letter – from the response team xx June 20xx U.S. Food and Drug Administration c/o <name>, Compliance Officer <address> <city>, <state> <zip> Re: Warning Letter xxx Dear Mr. xxx: This letter provides the response from <company name> to the Food and Drug Administration’s (FDA) Warning Letter dated xxx (Attachment 1) related to findings from FDA’s inspection of xxx facility on xxx through xxx. As the Warning Letter notes, xxx responded to the FDA Form 483 on xxx (Attachment 2 for the 483 and original response) but notes that it “did not provide any detailed information regarding proposed corrective actions.” To address this point, xxx is also including a more in-depth response, as part of this letter to the original 483 observations. xxx takes seriously its responsibilities in providing a quality product to the public. It continues to be xxx objective to operate in accordance with current regulations as stipulated by the US FDA. We value your communication and commit to meeting current GMP requirements. To this end, xxx has executed xxx critically important actions:
  • 17. W.L. Observation During the inspection, our investigators observed and documented xxx conditions. An analysis of your xxx collected during the inspection found significant xxx contamination. Response In conjunction with the conditions noted, xxx has initiated the following: xxx Implementation and maintenance of a clean and compliant environment has been executed as detailed previously but includes the following highlights: xxx Pursuant to the situation as outlined by the FDA testing of the xxx, xxx initiated a recall of the lot in xxx. The investigation into the situation that caused this incident indicated the following highlights: xxx Root Cause of the Situation: xxx Action Plan As applicable… Due Date
  • 18. Beyond the Context of the Direct Observations • A systemic response to any audit observations must equate to a systemic resolution to any issues within the firm. • This action requires further evaluation than just actions in a system at a company site. • The FDA in particular will require that all company sites implement corrective actions along the same plan of action. • Failure to do so may result in further regulatory actions. • Programs need to be established which require any observations and the responses to be circulated for evaluation within a company to determine if other areas are non-compliant.
  • 19. Be Sure to Visit Us On-Line or Call… Our website is filled with lots of tips and guidance on FDA 483’s, Warning Letters and more. Visit us at: www.Compliance-Insight.com You can easily contact us for more help in dealing with FDA Warning Letters by calling us at 513-860-3512
  • 20. www.Compliance-Insight.com Call us at 513-860-3512 Email us at FDAWarningLetterTeam@Compliance-Insight.com Questions? Comments? We are happy to help you!